554 related articles for article (PubMed ID: 26181758)
1. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
2. Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
Clin Cancer Res; 2016 Dec; 22(23):5909-5914. PubMed ID: 27521449
[TBL] [Abstract][Full Text] [Related]
3. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
4. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
Anuradha S; Donovan PJ; Webb PM; Brand AH; Goh J; Friedlander M; Oehler MK; Quinn M; Steer C; Jordan SJ
Acta Oncol; 2016; 55(2):226-33. PubMed ID: 26079434
[TBL] [Abstract][Full Text] [Related]
5. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
Hanna RK; Poniewierski MS; Laskey RA; Lopez MA; Shafer A; Van Le L; Crawford J; Dale DC; Gehrig PA; Secord AA; Havrilesky LJ; Lyman GH
Gynecol Oncol; 2013 Apr; 129(1):74-80. PubMed ID: 23262376
[TBL] [Abstract][Full Text] [Related]
6. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Australian Ovarian Cancer Study Group ; Webb P;
Gynecol Oncol; 2013 May; 129(2):310-7. PubMed ID: 23403164
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
Tewari D; Java JJ; Salani R; Armstrong DK; Markman M; Herzog T; Monk BJ; Chan JK
J Clin Oncol; 2015 May; 33(13):1460-6. PubMed ID: 25800756
[TBL] [Abstract][Full Text] [Related]
9. Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?
Ivy SP; Beumer JH
JAMA Oncol; 2015 Sep; 1(6):732-3. PubMed ID: 26181495
[No Abstract] [Full Text] [Related]
10. Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
Tran AQ; Cohen JG; Li AJ
Gynecol Oncol; 2015 Aug; 138(2):263-6. PubMed ID: 26037901
[TBL] [Abstract][Full Text] [Related]
11. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
[TBL] [Abstract][Full Text] [Related]
12. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
[TBL] [Abstract][Full Text] [Related]
13. Dose-dense approaches to ovarian cancer treatment.
Katsumata N
Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Fauci JM; Whitworth JM; Schneider KE; Subramaniam A; Zhang B; Frederick PJ; Kilgore LC; Straughn JM
Gynecol Oncol; 2011 Sep; 122(3):532-5. PubMed ID: 21658751
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
Wright JD; Tian C; Mutch DG; Herzog TJ; Nagao S; Fujiwara K; Powell MA
Gynecol Oncol; 2008 Jun; 109(3):353-8. PubMed ID: 18407341
[TBL] [Abstract][Full Text] [Related]
17. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
Stocker G; Hacker UT; Fiteni F; John Mahachie J; Roth AD; Van Cutsem E; Peeters M; Lordick F; Mauer M
Eur J Cancer; 2018 Aug; 99():49-57. PubMed ID: 29906734
[TBL] [Abstract][Full Text] [Related]
18. Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA
Gynecol Oncol; 2018 Oct; 151(1):18-23. PubMed ID: 30135020
[TBL] [Abstract][Full Text] [Related]
19. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
20. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
